Author/Editor     Pečovnik-Balon, B; Drinovec, J
Title     Rekombinantni human eritropoetin II: lastne izkušnje pri bolnikih na hemodializi
Translated title     Recombinant erythropoietin II: our experiences at the patients on chronic hemodialysis
Type     članek
Source     Zdrav Vestn
Vol. and No.     Letnik 64, št. 7-8
Publication year     1995
Volume     str. 439-42
Language     slo
Abstract     Background. Recombinant human erythropoietin is a drug designed for patients with kidney failure ans anemia. We wished to compare the effect of intravenous and subcutaneous erythropoietin applications. Methods. From among 50 patients treated at Maribor Teaching Hospital by chronic hemodialysis, we chose 7 patients with average hemoglobin concentrations under 70 g/l. In a 20-month prospective clinical study we studied the subsequent intravenous and subcutaneous dosing of human erythropoietin. Results. The average subcutaneous dose amounted to 34 percent of the intravenous dose. Two patients were excluded from the study due to uncontrollable hypertension, in 4 patients a hypertension appeared which was controlled by medication. No other side effects were noted. During treatment, all patients required intravenous applications of iron preparations. Conclusions. Recombinant human erythropoietin applied subcutaneously represents the most economic form of treatment for anemia within the complex of kidney failure. Simultaneous treatment with iron preparations and maintenance of normal blood pressure are required.
Summary     Izhodišča. Rekombinantni humani eritropoetin je zdravilo za bolnike z ledvično odpovedjo in anemijo. želeli smo primerjati učinkovitost intravensko in subkutano apliciranega eritropoetina. Metode. Izmed 50 bolnikov, ki so bili zdravljeni s kronično hemodializo v Splošni bolnišnici Maribor, smo izbrali sedem bolnikov, ki so imeli povprečno koncentracijo hemoglobina pod 70g/l. V prospektivni klinični študiji smo pri njih v dvajsetih mesecih preučili zaporedoma doziranje humanega eritropoetina intravensko in subkutano. Rezultati. Povprečna subkutana doza je bila 34 odst. intravenske doze. Dveh bolnikov nismo vključili v študijo zaradi neobvladljive hipertenzije, pri še štirih bolnikih pa se je pojavila hipertenzija, ki je bila obvladljiva z zdravili. Drugih stranskih pojavov nismo opazovali. Vsi bolniki so ob zdravljenju potrebovali intravenske preparate železa. Zaključki. Rekombinantni humani eritropoetin, dajan subkutano, je najbolj ekonomična oblika zdravljenja anemije v sklopu ledvične odpovedi. Sočasno je potrebno zdravljenje z železom in vzdrževanje normalnega krvnega tlaka.
Descriptors     ANEMIA
HEMODIALYSIS
ERYTHROPOIETIN
RECOMBINANT PROTEINS
DRUG EVALUATION